Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 77

Sort by

Sort Order Select

Journal Articles

Harnessing Btki Therapy By CDK4/6i Control of T Effector Memory Cells and T Cell Surveillance in Mantle Cell Lymphoma

Maurizio Di Liberto, Yang Hu, Xiangao Huang, Giorgio Inghirami, Kevin Wang, Christina Lee, Kami J. Maddocks, Kristie A. Blum, Jia Ruan, John P. Leonard, Nancy L. Bartlett, Peter Martin, Olivier Elemento, Selina Chen-Kiang

Blood (2023) 142 (Supplement 1): 50.

https://doi.org/10.1182/blood-2023-190308

Published: 2023

Journal Articles

PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma

Blood (2023) 142 (10): 887–902.

https://doi.org/10.1182/blood.2022019419

Published: 2023

Includes: Supplemental data

Journal Articles

Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL

Blood (2023) 141 (18): 2194–2205.

https://doi.org/10.1182/blood.2022018254

Published: 2023

Includes: Supplemental data

Journal Articles

Endothelial cell–leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities

Blood (2023) 141 (5): 503–518.

https://doi.org/10.1182/blood.2022015414

Published: 2023

Includes: Supplemental data

Journal Articles

Quantitative Cytogenetic Analysis with karyoParser Allows for More Precise Identification of Disease Biology, Clonal Evolution, and Etiology of Relapse in Acute Myeloid Leukemia

Deepika Dilip, Andriy Derkach, Kamal Menghrajani, Aaron D Goldberg, Hannah May, Virginia M. Klimek, Pallavi K Galera, Wenbin Xiao, Yanming Zhang, Olivier Elemento, Ross L. Levine, Jacob L Glass

Blood (2022) 140 (Supplement 1): 9119–9121.

https://doi.org/10.1182/blood-2022-170847

Published: 2022

Journal Articles

The Single-Cell Pathology Landscape of Diffuse Large B Cell Lymphoma

Dylan McNally, Andrew Lytle, Hiranmayi Ravichandran, Wayne Tam, Christian Steidl, David W. Scott, Ari Melnick, Olivier Elemento

Blood (2022) 140 (Supplement 1): 162–163.

https://doi.org/10.1182/blood-2022-169912

Published: 2022

Journal Articles

Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma

Jia Ruan, John P. Leonard, Gui Zhen Chen, Zhengming Chen, John N. Allan, Sarah C. Rutherford, Brittany Hobbie, Katie Greig, Amelyn Rodriguez, Wayne Tam, David A. Bond, Bijal D. Shah, Kami J. Maddocks, Bhavneet Binder, Giorgio Inghirami, Olivier Elemento, Selina Chen-Kiang, Peter Martin

Blood (2022) 140 (Supplement 1): 175–177.

https://doi.org/10.1182/blood-2022-158656

Published: 2022

Journal Articles

Combined Inhibition of CDK2 and BCL2 Overrides Resistance to Targeting BTK and CDK4/6 in Mantle Cell Lymphoma Therapy

Haya Y. Al-Ansari, Saira Bashir, Adrienne Cui, Xiangao Huang, Yang Hu, Peter Martin, Olivier Elemento, Maurizio Di Liberto, Selina Chen-Kiang

Blood (2022) 140 (Supplement 1): 495–496.

https://doi.org/10.1182/blood-2022-167307

Published: 2022

Journal Articles

The FOXO1 TAD -p300-Mediated Lineage Survival Transcription Program Is a Targetable Dependency of Mantle Cell Lymphoma

Ja-Young Jang, Heng Pan, Maurizio Di Liberto, Lapo Alinari, Giorgio Inghirami, Robert A. Baiocchi, Olivier Elemento, Selina Chen-Kiang, Jihye Paik

Blood (2022) 140 (Supplement 1): 1692–1693.

https://doi.org/10.1182/blood-2022-165655

Published: 2022

Journal Articles

PRMT5 Inhibition Alters Mitochondrial Dynamics in Mantle Cell Lymphoma Creating Vulnerability to BH3 Mimetic Compounds

Claire Hinterschied, Fiona Brown, Janani Ravikrishnan, JoBeth Helmig-Mason, Kaylee R. Harrison, Aneeq Yasin, Shelby Sloan, Mackenzie Long, Neha Bhagwat, Kris Vaddi, Peggy Scherle, Jennifer A. Woyach, Selina Chen-Kiang, Olivier Elemento, Jihye Paik, Robert A. Baiocchi

Blood (2022) 140 (Supplement 1): 3118–3119.

https://doi.org/10.1182/blood-2022-167712

Published: 2022

Journal Articles

PRMT5 Inhibition Potentiates Anti-Tumor Immune Targeting of EBV-Driven B Cell Lymphoproliferative Disease

Blood (2022) 140 (Supplement 1): 3116–3117.

https://doi.org/10.1182/blood-2022-167988

Published: 2022

Journal Articles

Dynamic Immune Surveillance in Durable Clinical Response to Combined BTK and BCL2 Inhibition in MCL at Longitudinal Single-Cell Resolution

Kevin Wang, Maurizio Di Liberto, Yang Hu, Xiangao Huang, Rachel M Koldej, David Ritchie, Peter Martin, Giorgio Inghirami, Olivier Elemento, Constantine S. Tam, Selina Chen-Kiang

Blood (2021) 138 (Supplement 1): 1323.

https://doi.org/10.1182/blood-2021-152908

Published: 2021

Journal Articles

FOXO1 Dependent Transcription Network Is a Targetable Vulnerability of Mantle Cell Lymphoma

Ja-Young Jang, Inah Hwang, Heng Pan, Michael Kluk, Jun Yao, Xiangao Huang, Maurizio Di Liberto, Zhengming Chen, Karla V Ballman, Lewis C Cantley, Giorgio Inghirami, Olivier Elemento, Robert Baiocchi, Selina Chen-Kiang, Sandro Belvedere, Hongwu Zheng, Jihye Paik

Blood (2021) 138 (Supplement 1): 30.

https://doi.org/10.1182/blood-2021-153378

Published: 2021

Journal Articles

A Predictive Endothelial-Leukemia Pre-Clinical Platform to Uncover Drug Vulnerabilities for Personalized Treatments

Blood (2021) 138 (Supplement 1): 704.

https://doi.org/10.1182/blood-2021-153300

Published: 2021

Journal Articles

PRMT5 Inhibition Promotes FOXO1 Tumor Suppressor Activity to Drive a Pro-Apoptotic Program That Creates Vulnerability to Combination Treatment with Venetoclax in Mantle Cell Lymphoma

Blood (2021) 138 (Supplement 1): 681.

https://doi.org/10.1182/blood-2021-153733

Published: 2021

Journal Articles

Single Cell ATAC Lineage Deconvolution Reveals Overlapping Subclones in Epigenetically Distinct AML Samples

Deepika Dilip, Richard Koche, Kamal Menghrajani, Ari Melnick, Olivier Elemento, Ross L. Levine, Jacob L Glass

Blood (2021) 138 (Supplement 1): 2381.

https://doi.org/10.1182/blood-2021-154517

Published: 2021

Journal Articles

Molecular Evolution of Classical Hodgkin Lymphoma Revealed Though Whole Genome Sequencing of Hodgkin and Reed-Sternberg Cells

Blood (2021) 138 (Supplement 1): 805.

https://doi.org/10.1182/blood-2021-148663

Published: 2021

Journal Articles

Selective STAT3 Degraders Dissect Peripheral T-Cell Lymphomas Vulnerabilities Empowering Personalized Regimens

Blood (2021) 138 (Supplement 1): 865.

https://doi.org/10.1182/blood-2021-153995

Published: 2021

Journal Articles

HHV-6 in the Lymphoma Microenvironment: Both Chicken and Egg?

Genevieve M Crane, Dmitry Tychinin, Anton Karelin, Aleksandr Cherdintsev, Olga Kudryashova, Evgeniy Egorov, Sandrine Degryse, Nikita Kotlov, Alexander Bagaev, Joseph Casano, Jonathan Reichel, Lisa Giulino Roth, Mikhail Roshal, Sakellarios Zairis, Raul Rabadan, Olivier Elemento, Giorgio Inghirami, Ethel Cesarman

Blood (2021) 138 (Supplement 1): 1377.

https://doi.org/10.1182/blood-2021-146336

Published: 2021

Journal Articles

High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study

Blood (2021) 138 (Supplement 1): 138.

https://doi.org/10.1182/blood-2021-145495

Published: 2021

NARROW

Harnessing Btki Therapy By CDK4/6i Control of T Effector Memory Cells and T Cell Surveillance in Mantle Cell Lymphoma

PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma

Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL

Endothelial cell–leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities

Quantitative Cytogenetic Analysis with karyoParser Allows for More Precise Identification of Disease Biology, Clonal Evolution, and Etiology of Relapse in Acute Myeloid Leukemia

The Single-Cell Pathology Landscape of Diffuse Large B Cell Lymphoma

Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma

Combined Inhibition of CDK2 and BCL2 Overrides Resistance to Targeting BTK and CDK4/6 in Mantle Cell Lymphoma Therapy

The FOXO1 TAD -p300-Mediated Lineage Survival Transcription Program Is a Targetable Dependency of Mantle Cell Lymphoma

PRMT5 Inhibition Alters Mitochondrial Dynamics in Mantle Cell Lymphoma Creating Vulnerability to BH3 Mimetic Compounds

PRMT5 Inhibition Potentiates Anti-Tumor Immune Targeting of EBV-Driven B Cell Lymphoproliferative Disease

Dynamic Immune Surveillance in Durable Clinical Response to Combined BTK and BCL2 Inhibition in MCL at Longitudinal Single-Cell Resolution

FOXO1 Dependent Transcription Network Is a Targetable Vulnerability of Mantle Cell Lymphoma

A Predictive Endothelial-Leukemia Pre-Clinical Platform to Uncover Drug Vulnerabilities for Personalized Treatments

PRMT5 Inhibition Promotes FOXO1 Tumor Suppressor Activity to Drive a Pro-Apoptotic Program That Creates Vulnerability to Combination Treatment with Venetoclax in Mantle Cell Lymphoma

Single Cell ATAC Lineage Deconvolution Reveals Overlapping Subclones in Epigenetically Distinct AML Samples

Molecular Evolution of Classical Hodgkin Lymphoma Revealed Though Whole Genome Sequencing of Hodgkin and Reed-Sternberg Cells

Selective STAT3 Degraders Dissect Peripheral T-Cell Lymphomas Vulnerabilities Empowering Personalized Regimens

HHV-6 in the Lymphoma Microenvironment: Both Chicken and Egg?

High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only